Estradiol, tamoxifen, and flaxseed alter IL-1β and IL-1Ra levels in normal human breast tissue in vivo

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 11, 2012, Pages

  Abrahamsson, Annelie ^a   Morad, Vivian ^a   Saarinen, Niina M ^a,b   Dabrosin, Charlotta ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PROGESTERONE; TAMOXIFEN;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST REDUCTION; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET; DRUG ACTIVITY; DRUG BLOOD LEVEL; EARLY CANCER; ENZYME RELEASE; FEMALE; FOLLICULAR PHASE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LINSEED; LUTEAL PHASE; MICRODIALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST; ESTRADIOL; ESTROGENS; FEMALE; FLAX; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MIDDLE AGED; SEEDS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84868626677     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2288     Document Type: Article

References (40)

1. Hanahan D, Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144:646-674
2. Dinarello CA 1997 Interleukin-1. Cytokine Growth Factor Rev 8:253-265 (Pubitemid 28201653)
3. Dinarello CA 2010 Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 29:317-329
4. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, Segal S, Voronov E 2006 Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 42:751-759
5. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN 2003 IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100:2645-2650 (Pubitemid 36297552)
6. Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S 2004 A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J 18:161-163
7. Lindahl G, Saarinen N, Abrahamsson A, Dabrosin C 2011 Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res 71:51-60
8. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ 2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319-1329
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333 (Pubitemid 34761611)
10. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA 2005 Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 34:405-412 (Pubitemid 40645331)
11. Howe GR, Hirohata T, Hislop TG, Iscovich JM, Yuan JM, Katsouyanni K, Lubin F, Marubini E, Modan B, Rohan T, Toniolo P, Shunzhang Y 1990 Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst 82:561-569 (Pubitemid 20115446)
12. Touillaud MS, Thiébaut AC, Fournier A, Niravong M, Boutron-Ruault MC, Clavel-Chapelon F 2007 Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. J Natl Cancer Inst 99:475-486 (Pubitemid 47078736)
13. Trock BJ, Hilakivi-Clarke L, Clarke R 2006 Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 98:459-471
14. Guglielmini P, Rubagotti A, Boccardo F 2012 Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. Breast Cancer Res Treat 132:661-668
15. Buck K, Zaineddin AK, Vrieling A, Heinz J, Linseisen J, Flesch-Janys D, Chang-Claude J 2011 Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer. Br J Cancer 105:1151-1157
16. Buck K, Vrieling A, Zaineddin AK, Becker S, Hüsing A, Kaaks R, Linseisen J, Flesch-Janys D, Chang-Claude J 2011 Serum enterolactone and prognosis of postmenopausal breast cancer. J Clin Oncol 29:3730-3738
17. Olsen A, Christensen J, Knudsen KE, Johnsen NF, Overvad K, Tjønneland A 2011 Prediagnostic plasma enterolactone levels and mortality among women with breast cancer. Breast Cancer Res Treat 128:883-889
18. Dabrosin C 2001 Technical aspects of microdialysis of human breast. Scand J Clin Lab Invest 61:269-272 (Pubitemid 32565600)
19. Dabrosin C 2003 Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. J Clin Endocrinol Metab 88:2695-2698 (Pubitemid 36724444)
20. Dabrosin C, Hallström A, Ungerstedt U, Hammar M 1997 Microdialysis of human breast tissue during the menstrual cycle. Clin Sci (Lond) 92:493-496 (Pubitemid 27214209)
21. Dabrosin C, Ollinger K, Ungerstedt U, Hammar M 1997 Variability of glutathione levels in normal breast tissue and subcutaneous fat during the menstrual cycle: an in vivo study with microdialysis technique. J Clin Endocrinol Metab 82:1382-1384 (Pubitemid 27200405)
22. Åberg UW, Saarinen N, Abrahamsson A, Nurmi T, Engblom S, Dabrosin C 2011 Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo. PLoS One 6:e25720
23. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, Sonoda KH, Saijo Y, Nukiwa T, Strieter RM, Ishibashi T, Kuwano M, Ono M 2005 Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 β-induced neovascularization and tumor growth. J Clin Invest 115:2979-2991 (Pubitemid 41567564)
24. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, Turkel G, Polverini PJ, Goldberg ID, Rosen EM 1997 Expression of interleukin-1β in human breast carcinoma. Cancer 80:421-434 (Pubitemid 27323412)
25. Roy D, Cai Q, Felty Q, Narayan S 2007 Estrogen-induced generation of reactive oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev 10:235-257 (Pubitemid 47057178)
26. Dabrosin C 2005 Microdialysis - an in vivo technique for studies of growth factors in breast cancer. Front Biosci 10:1329-1335
27. Dabrosin C 2005 Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin Cancer Res 11:8036-8041 (Pubitemid 41698745)
28. Garvin S, Dabrosin C 2008 In vivo measurement of tumor estradiol and vascular endothelial growth factor in breast cancer patients. BMC Cancer 8:73
29. Ruh MF, Bi Y, D'Alonzo R, Bellone CJ 1998 Effect of estrogens on IL-1β promoter activity. J Steroid Biochem Mol Biol 66:203-210 (Pubitemid 28401694)
30. Frasor J, Chang EC,KommB, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS 2006 Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66:7334-7340 (Pubitemid 44197716)
31. Chen J, Stavro PM, Thompson LU 2002 Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 43:187-192 (Pubitemid 36134093)
32. Kramer PR, Wray S 2002 17-β-Estradiol regulates expression of genes that function in macrophage activation and cholesterol homeostasis. J Steroid Biochem Mol Biol 81:203-216 (Pubitemid 34879931)
33. Hulka BS, Stark AT 1995 Breast cancer: cause and prevention. Lancet 346:883-887
34. Pike MC, Pearce CL, Wu AH 2004 Prevention of cancers of the breast, endometrium and ovary. Oncogene 23:6379-6391 (Pubitemid 39265506)
35. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388 (Pubitemid 28439961)
36. Saarinen NM, Tuominen J, Santti R, Pylkkänen L 2008 Anticarcinogenic effects of lignans in breast and prostate - a critical review of the current knowledge. In: Yagasaki K, Yamazaki M, eds. Bromacology: pharmacology of foods and their components. Kerala, India: Research Signpost
37. Saarinen NM, Abrahamsson A, Dabrosin C 2010 Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. Int J Cancer 127:737-745
38. Bergman Jungeström M, Thompson LU, Dabrosin C 2007 Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 13:1061-1067 (Pubitemid 46340386)
39. Thompson LU, Chen JM, Li T, Strasser-Weippl K, Goss PE 2005 Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 11:3828-3835 (Pubitemid 40685603)
40. Welch HG, Black WC 1997 Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 127:1023-1028 (Pubitemid 27516615)